GlassScriptPhysician profile
Joyce Lockard
NPI 1013163054
$3,403.96
in general payments reported to CMS, 2019-2025
32 companies · $275 in 2025
The $275 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $654 · 2022: $915 · 2023: $908 · 2024: $653 · 2025: $275.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,835.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,835.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $552.66 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $368.94 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $346.56 | 2022-2025 | |
| Lilly USA, LLC | $271.38 | 2021-2025 | Mounjaro, Zepbound |
| Lundbeck LLC | $209.68 | 2023-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $184.89 | 2021-2025 | Rexulti, Abilify Asimtufii, Nuedexta |
| Merck Sharp & Dohme LLC | $173.13 | 2021-2024 | Verquvo, Steglatro, Belsomra |
| Avanir Pharmaceuticals, INC. | $144.44 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $124.10 | 2021-2023 | Trintellix |
| Astrazeneca Pharmaceuticals LP | $112.98 | 2022-2025 | Breztri, Airsupra |
| Exact Sciences Corporation | $103.53 | 2023-2025 | Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $99.11 | 2022-2024 | Nexletol |
| Glaxosmithkline, LLC. | $82.31 | 2021-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Astellas Pharma US INC | $69.27 | 2021-2024 | Veozah, Myrbetriq |
| Novartis Pharmaceuticals Corporation | $68.51 | 2021-2023 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $61.33 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $54.87 | 2021 | |
| Amgen INC. | $50.82 | 2023-2024 | Otezla, Repatha |
| Kowa Pharmaceuticals America, INC. | $43.80 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.87 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $39.17 | 2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $29.05 | 2021-2022 | |
| Amarin Pharma, INC. | $19.63 | 2021 | |
| Axsome Therapeutics, INC. | $19.33 | 2023 | Auvelity |
| Idorsia Pharmaceuticals US INC | $19.19 | 2023 | Quviviq |
| Phathom Pharmaceuticals, INC. | $19.18 | 2024 | Voquezna |
| Redhill Biopharma INC. | $19.14 | 2021 | |
| Mylan Specialty L.P. | $18.95 | 2023 | Yupelri |
| Philips North America LLC | $16.25 | 2022 | |
| Xeris Pharmaceuticals, INC. | $14.91 | 2025 | Keveyis |
| Genentech USA, INC. | $14.87 | 2021 | |
| Eisai INC. | $12.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joyce Lockard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.